CTAD 2025 | The development and use of biomarkers for combination therapy in Alzheimer’s disease

Suzanne Schindler, MD, PhD, Washington University in St. Louis School of Medicine, St. Louis, MO, discusses the need for combination therapies in Alzheimer’s disease, and highlights the importance of biomarkers in determining the optimal treatment approach for individual patients. Dr Schindler emphasizes the complexity of Alzheimer’s disease, with multiple pathologies often present, and the need for more advanced biomarkers to capture the complexity of the disease. This interview took place at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.